ES2656000T3 - Anticuerpos frente a CGRP - Google Patents
Anticuerpos frente a CGRP Download PDFInfo
- Publication number
- ES2656000T3 ES2656000T3 ES11792989.3T ES11792989T ES2656000T3 ES 2656000 T3 ES2656000 T3 ES 2656000T3 ES 11792989 T ES11792989 T ES 11792989T ES 2656000 T3 ES2656000 T3 ES 2656000T3
- Authority
- ES
- Spain
- Prior art keywords
- seq
- antibodies against
- lcdr3
- lcdr1
- lcdr2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 title 1
- 102100025588 Calcitonin gene-related peptide 1 Human genes 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- DNKYDHSONDSTNJ-XJVRLEFXSA-N chembl1910953 Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)N)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CN=CN1 DNKYDHSONDSTNJ-XJVRLEFXSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57527—Calcitonin gene related peptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57545—Neuropeptide Y
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Un anticuerpo frente a CGRP humano técnicamente diseñado que comprende una región variable de la cadena ligera (LCVR) y una región variable de la cadena pesada (HCVR), en el que dicha LCVR comprende las secuencias de aminoácidos de LCDR1, LCDR2, LCDR3 y la HCVR comprende las secuencias de aminoácidos de HCDR1, HCDR2, HCDR3, en el que LCDR1 es RASKDISKYLN (SEQ ID NO: 6), LCDR2 es YTSGYHS (SEQ ID NO: 7), LCDR3 es QQGDALPPT (SEQ ID NO: 5), HCDR1 es GYTFGNYWMQ (SEQ ID NO: 12), HCDR2 es AIYEGTGKTVYIQKFAD (SEQ ID NO: 16) y HCDR3 es LSDYVSGFGY (SEQ ID NO: 39).
Description
X1 es Q, R o K; X2 es D o P; X3 es D o S; X4 es N o K; y X5 es G o E.
- Anticuerpo
- LCDR1 LCDR2 LCDR3
- I
- GYTFGNYWMQ (SEQ ID NO:12) AIYEGTGDTRYIQKFAG (SEQ ID NO: 13) LSDYVSGFSY (SEQ ID NO:14)
- II
- GYTFGNYWMQ (SEQ ID NO:12) AIYEGTGKTVYIQKFAG (SEQ ID NO: 15 LSDYVSGFSY (SEQ ID NO:14)
- III
- GYTFGNYWMQ (SEQ ID NO:12) AIYEGTGKTVYIQKFAD (SEQ ID NO: 16) LSDYVSGFGY (SEQ ID NO:39)
- IV
- GYTFGNYWMQ (SEQ ID NO:12) AIYEGTGKTVYIQKFAG (SEQ ID NO: 15) LSDYVSGFGY (SEQ ID NO:39)
- V
- GYTFGNYWMQ (SEQ ID NO:12) AIYEGTGKTVYIQKFAG (SEQ ID NO: 15) LSDYVSGFGY (SEQ ID NO:39)
- consenso
- GYTFGNYWMQ (SEQ ID NO:12) AIYEGTGX6TX7YIQKFAX8 (SEQ ID NO:37) LSDYVSGFX9Y (SEQ ID NO:38)
X6 es K o D; X7 es V o R; X8 es D oG; y X9 es G o S.
11
Claims (1)
-
imagen1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35332310P | 2010-06-10 | 2010-06-10 | |
US353323P | 2010-06-10 | ||
PCT/US2011/039381 WO2011156324A1 (en) | 2010-06-10 | 2011-06-07 | Cgrp antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2656000T3 true ES2656000T3 (es) | 2018-02-22 |
Family
ID=45096388
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES17201603T Active ES2930321T3 (es) | 2010-06-10 | 2011-06-07 | Anticuerpos frente a CGRP |
ES11792989.3T Active ES2656000T3 (es) | 2010-06-10 | 2011-06-07 | Anticuerpos frente a CGRP |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES17201603T Active ES2930321T3 (es) | 2010-06-10 | 2011-06-07 | Anticuerpos frente a CGRP |
Country Status (34)
Country | Link |
---|---|
US (3) | US9073991B2 (es) |
EP (2) | EP2579894B1 (es) |
JP (2) | JP6021806B2 (es) |
KR (1) | KR101489566B1 (es) |
CN (2) | CN104292332B (es) |
AR (1) | AR081434A1 (es) |
AU (1) | AU2011265050B2 (es) |
BR (1) | BR112012031501B1 (es) |
CA (1) | CA2802102C (es) |
CY (2) | CY1119789T1 (es) |
DK (1) | DK2579894T3 (es) |
EA (1) | EA022931B1 (es) |
ES (2) | ES2930321T3 (es) |
HK (1) | HK1203211A1 (es) |
HR (1) | HRP20171992T1 (es) |
HU (2) | HUE038135T2 (es) |
IL (2) | IL222885B (es) |
JO (1) | JO3330B1 (es) |
LT (2) | LT2579894T (es) |
LU (1) | LUC00112I2 (es) |
ME (1) | ME02862B (es) |
MX (2) | MX363209B (es) |
NL (1) | NL300979I2 (es) |
NO (2) | NO2579894T3 (es) |
NZ (1) | NZ603607A (es) |
PL (1) | PL2579894T3 (es) |
PT (1) | PT2579894T (es) |
RS (1) | RS56638B1 (es) |
SG (1) | SG185648A1 (es) |
SI (1) | SI2579894T1 (es) |
TW (1) | TWI423818B (es) |
UA (1) | UA109658C2 (es) |
WO (1) | WO2011156324A1 (es) |
ZA (1) | ZA201208996B (es) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3842458A1 (en) | 2005-11-14 | 2021-06-30 | Teva Pharmaceuticals International GmbH | Antagonist antibodies directed against calcitonin gene-related peptide |
EP3441087A1 (en) | 2008-03-04 | 2019-02-13 | Teva Pharmaceuticals International GmbH | Methods of treating chronic pain |
KR101519192B1 (ko) | 2009-08-28 | 2015-05-11 | 리나트 뉴로사이언스 코프. | 칼시토닌 유전자-관련된 펩티드에 대해 지시된 길항제 항체의 투여에 의한 내장 통증의 치료 방법 |
JO3330B1 (ar) * | 2010-06-10 | 2019-03-13 | Lilly Co Eli | الأجسام المضادة cgrp |
US9708393B2 (en) | 2011-05-20 | 2017-07-18 | Alderbio Holdings Llc | Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers |
WO2012162243A2 (en) | 2011-05-20 | 2012-11-29 | Alderbio Holdings Llc | Anti-cgrp compositions and use thereof |
EP2709662B1 (en) | 2011-05-20 | 2019-07-31 | AlderBio Holdings LLC | Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea |
KR101935088B1 (ko) | 2012-08-24 | 2019-01-04 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신 |
US20170114122A1 (en) | 2015-10-23 | 2017-04-27 | Alderbio Holdings Llc | Regulation of glucose metabolism using anti-cgrp antibodies |
JP6568099B2 (ja) | 2014-03-21 | 2019-08-28 | テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーTeva Pharmaceuticals International GmbH | カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体及びその使用方法 |
US10556945B2 (en) | 2014-03-21 | 2020-02-11 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
JP6581656B2 (ja) | 2014-10-24 | 2019-09-25 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | グルカゴンおよびglp−1受容体のコアゴニスト |
TWI595006B (zh) * | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗pd-1抗體類和使用彼等之方法 |
JOP20200116A1 (ar) | 2015-04-24 | 2017-06-16 | Amgen Inc | طرق لعلاج أو الوقاية من الصداع النصفي |
AR104847A1 (es) * | 2015-06-17 | 2017-08-16 | Lilly Co Eli | Formulación de anticuerpo anti-cgrp |
JP6592600B2 (ja) * | 2015-10-30 | 2019-10-16 | イーライ リリー アンド カンパニー | 抗cgrp/抗il−23二重特異性抗体及びその使用 |
CN105483091A (zh) * | 2015-12-29 | 2016-04-13 | 天津三箭生物技术股份有限公司 | 小鼠抗人Calcitonin单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株 |
JP2019501152A (ja) * | 2016-01-28 | 2019-01-17 | イーライ リリー アンド カンパニー | Cgrp抗体及びその使用 |
EP3411066A1 (en) | 2016-02-01 | 2018-12-12 | Eli Lilly and Company | Parathyroid hormone anti-rankl antibody fusion compounds |
CN109996544A (zh) | 2016-06-27 | 2019-07-09 | 加利福尼亚大学董事会 | 癌症治疗组合 |
EP3515937A1 (en) * | 2016-09-23 | 2019-07-31 | Teva Pharmaceuticals International GmbH | Treating refractory migraine |
US20180111984A1 (en) | 2016-09-23 | 2018-04-26 | Teva Pharmaceuticals International Gmbh | Treating cluster headache |
MX2019010397A (es) | 2017-03-02 | 2020-08-20 | Beth Israel Deaconess Medical Ct Inc | Seleccion de pacientes de cefalea que responden a anticuerpos dirigidos contra el peptido relacionado con el gen de la calcitonina. |
TW201902926A (zh) * | 2017-05-03 | 2019-01-16 | 美商美國禮來大藥廠 | 抗cgrp/抗il-23雙特異性抗體及其用途 |
EP3642218A4 (en) * | 2017-06-21 | 2021-04-07 | Cephalon, Inc. | CATION EXCHANGE CHROMATOGRAPHY WASH PAD |
TWI754772B (zh) * | 2017-09-06 | 2022-02-11 | 美商美國禮來大藥廠 | 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法 |
UY38050A (es) | 2018-01-12 | 2019-07-31 | Amgen Inc | Anticuerpos pac1 y sus usos referencia cruzada a solicitudes relacionadas |
WO2019231800A1 (en) | 2018-05-31 | 2019-12-05 | Eli Lilly And Company | Anti-cgrp antibodies for treating menstrual-related migraines |
WO2020041468A1 (en) | 2018-08-22 | 2020-02-27 | Eli Lilly And Company | Anti-cgrp antibodies for treatment-resistant patients |
CN113227140A (zh) | 2019-01-08 | 2021-08-06 | H.隆德贝克有限公司 | 使用抗cgrp抗体急性治疗和快速治疗头痛 |
EP3744400A1 (en) * | 2019-05-28 | 2020-12-02 | Etablissement Français du Sang | Car-t cells targeting il-1rap and their use in acute myeloid leukemia (aml) |
CN114127110B (zh) * | 2019-05-30 | 2022-07-01 | 山东博安生物技术股份有限公司 | 抗cgrp抗体及其应用 |
JP7551744B2 (ja) | 2019-10-15 | 2024-09-17 | イーライ リリー アンド カンパニー | 組換え操作された、リパーゼ/エステラーゼ欠損哺乳動物細胞株 |
CA3212151A1 (en) | 2021-03-02 | 2022-09-09 | Cgrp Diagnostics Gmbh | Treatment and/or reduction of occurrence of migraine |
WO2023161528A1 (en) | 2022-02-28 | 2023-08-31 | Tridem Bioscience Gmbh & Co Kg | A CONJUGATE COMPRISING AT LEAST A ß-GLUCAN |
CN117586390A (zh) * | 2022-08-11 | 2024-02-23 | 上海君实生物医药科技股份有限公司 | 抗cgrp抗体及用途 |
CN118271438B (zh) * | 2024-05-27 | 2024-08-30 | 上海宏成药业有限公司 | 抗cgrp抗体或其抗原结合片段及其用途 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
RU2139351C1 (ru) * | 1991-04-25 | 1999-10-10 | Чугаи Сейяку Кабусики Кайся | Н- и l-цепи моноклонального антитела рм1 (монат) к рецептору il-6r человека и их v-области, модифицированная монат, его н- и l-цепи и их v-области, cdr- последовательности, днк-последовательности |
EP0940468A1 (en) * | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
WO2005035753A1 (ja) | 2003-10-10 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | 機能蛋白質を代替する二重特異性抗体 |
US20060228367A1 (en) * | 2005-04-08 | 2006-10-12 | Medimmune, Inc. | Antibodies against mammalian metapneumovirus |
EP3842458A1 (en) * | 2005-11-14 | 2021-06-30 | Teva Pharmaceuticals International GmbH | Antagonist antibodies directed against calcitonin gene-related peptide |
WO2007076336A1 (en) * | 2005-12-22 | 2007-07-05 | Eli Lilly And Company | Treatment of migraine with anti-cgrp antibodies |
EP3441087A1 (en) * | 2008-03-04 | 2019-02-13 | Teva Pharmaceuticals International GmbH | Methods of treating chronic pain |
EP3115062A1 (en) | 2008-03-04 | 2017-01-11 | Labrys Biologics Inc. | Methods of treating inflammatory pain |
JO3330B1 (ar) * | 2010-06-10 | 2019-03-13 | Lilly Co Eli | الأجسام المضادة cgrp |
-
2011
- 2011-05-31 JO JOP/2011/0177A patent/JO3330B1/ar active
- 2011-05-31 AR ARP110101867A patent/AR081434A1/es active IP Right Grant
- 2011-06-03 TW TW100119683A patent/TWI423818B/zh active
- 2011-06-07 PL PL11792989T patent/PL2579894T3/pl unknown
- 2011-06-07 MX MX2016005150A patent/MX363209B/es unknown
- 2011-06-07 EP EP11792989.3A patent/EP2579894B1/en active Active
- 2011-06-07 US US13/154,538 patent/US9073991B2/en active Active
- 2011-06-07 NO NO11792989A patent/NO2579894T3/no unknown
- 2011-06-07 CA CA2802102A patent/CA2802102C/en active Active
- 2011-06-07 KR KR1020127032068A patent/KR101489566B1/ko active IP Right Grant
- 2011-06-07 JP JP2013514281A patent/JP6021806B2/ja active Active
- 2011-06-07 ES ES17201603T patent/ES2930321T3/es active Active
- 2011-06-07 ME MEP-2017-280A patent/ME02862B/me unknown
- 2011-06-07 NZ NZ603607A patent/NZ603607A/en unknown
- 2011-06-07 EA EA201270769A patent/EA022931B1/ru not_active IP Right Cessation
- 2011-06-07 LT LTEP11792989.3T patent/LT2579894T/lt unknown
- 2011-06-07 MX MX2012014480A patent/MX340999B/es active IP Right Grant
- 2011-06-07 HU HUE11792989A patent/HUE038135T2/hu unknown
- 2011-06-07 AU AU2011265050A patent/AU2011265050B2/en active Active
- 2011-06-07 EP EP17201603.2A patent/EP3318272B1/en active Active
- 2011-06-07 PT PT117929893T patent/PT2579894T/pt unknown
- 2011-06-07 BR BR112012031501-3A patent/BR112012031501B1/pt active IP Right Grant
- 2011-06-07 SG SG2012084885A patent/SG185648A1/en unknown
- 2011-06-07 CN CN201410474677.9A patent/CN104292332B/zh active Active
- 2011-06-07 DK DK11792989.3T patent/DK2579894T3/en active
- 2011-06-07 WO PCT/US2011/039381 patent/WO2011156324A1/en active Application Filing
- 2011-06-07 ES ES11792989.3T patent/ES2656000T3/es active Active
- 2011-06-07 CN CN201180028611.1A patent/CN102946905B/zh active Active
- 2011-06-07 SI SI201131359T patent/SI2579894T1/en unknown
- 2011-06-07 RS RS20171265A patent/RS56638B1/sr unknown
- 2011-07-06 UA UAA201212663A patent/UA109658C2/ru unknown
-
2012
- 2012-11-05 IL IL222885A patent/IL222885B/en active Protection Beyond IP Right Term
- 2012-11-28 ZA ZA2012/08996A patent/ZA201208996B/en unknown
-
2015
- 2015-04-20 HK HK15103793.6A patent/HK1203211A1/xx unknown
- 2015-06-04 US US14/730,270 patent/US9505838B2/en active Active
- 2015-11-02 IL IL242409A patent/IL242409B/en active IP Right Grant
-
2016
- 2016-06-28 JP JP2016127666A patent/JP6466883B2/ja active Active
- 2016-11-02 US US15/341,166 patent/US20170073403A1/en not_active Abandoned
-
2017
- 2017-12-21 HR HRP20171992TT patent/HRP20171992T1/hr unknown
-
2018
- 2018-01-18 CY CY20181100064T patent/CY1119789T1/el unknown
-
2019
- 2019-04-02 CY CY2019017C patent/CY2019017I2/el unknown
- 2019-04-02 HU HUS1900020C patent/HUS1900020I1/hu unknown
- 2019-04-05 NO NO2019017C patent/NO2019017I1/no unknown
- 2019-04-09 LU LU00112C patent/LUC00112I2/fr unknown
- 2019-04-11 NL NL300979C patent/NL300979I2/nl unknown
- 2019-04-12 LT LTPA2019011C patent/LTC2579894I2/lt unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2656000T3 (es) | Anticuerpos frente a CGRP | |
ES2564252T3 (es) | Anticuerpos anti-péptido beta-amiloide N3pGlu y usos de los mismos | |
PE20200011A1 (es) | ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
HRP20211343T1 (hr) | Protutijela protiv dkk-1 | |
PE20210045A1 (es) | Anticuerpos agonistas contra pd-1 y usos de estos | |
PE20141147A1 (es) | Anticuerpos a pcsk9 y usos de los mismos | |
NZ600768A (en) | Human antibodies to human angiopoietin-like protein 4 | |
AR081427A1 (es) | Metodo para preparar anticuerpos con propiedades mejoradas | |
ES2670621T3 (es) | Anticuerpos que se unen a OX40 y sus usos | |
CO6230999A2 (es) | Anticuerpo anti-esclerostina | |
PE20141151A1 (es) | Proteinas de union al antigeno cd27l | |
RS54111B1 (en) | ANTI-ALPHA 2 INTEGRIN ANTIBODIES AND THEIR USES | |
NZ610294A (en) | Human antibodies to human tnf-like ligand 1a (tl1a) | |
ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
PE20140882A1 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
PE20130226A1 (es) | Anticuerpos hacia gdf8 humano | |
ES2685823T3 (es) | Anticuerpos antagonistas anti-CD40 | |
PE20191408A1 (es) | Proteinas de union a antigeno st2 | |
PE20091261A1 (es) | Anticuerpos anti-hepcidina | |
NZ628943A (en) | Human antibodies to clostridium difficile toxins | |
RU2011142183A (ru) | Средство для лечения ревматоидного артрита | |
PE20220708A1 (es) | Anticuerpos anti-cd73 | |
HRP20161587T1 (hr) | Protutijela protiv bmp-6 | |
PE20141683A1 (es) | Anticuerpos monoclonales especificos para el antigeno m2-1 del virus respiratorio sincicial (vrs) | |
PE20201494A1 (es) | Anticuerpo anti-pacap |